Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 -1.53%90 EV-to-EBITDA is 9.26 as of Aug. 13, 2026, which is 46% below its 10-year median of 17.07. GuruFocus rates BSP:RADL3 with a GF Score™ of 90/100 and a GF Value™ of R$27.20 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Raia Drogasil ranks better than 59.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Raia Drogasil's enterprise value is R$39,414 Mil.
Raia Drogasil's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was R$4,258 Mil. Therefore, Raia Drogasil's EV-to-EBITDA for today is 9.26.
The historical rank and industry rank for Raia Drogasil's EV-to-EBITDA or its related term are showing as below:
BSP:RADL3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.22 Med: 17.07 Max: 33.82
Current: 9.26
During the past 13 years, the highest EV-to-EBITDA of Raia Drogasil was 33.82. The lowest was 8.22. And the median was 17.07.
BSP:RADL3's EV-to-EBITDA is ranked better than 59.26% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.81
vs BSP:RADL3: 9.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Raia Drogasil's PE Ratio (TTM) for today is calculated as:
Raia Drogasil's share price for today is R$18.00.
Raia Drogasil's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.811.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Raia Drogasil's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's EV-to-EBITDA falls into.
Raia Drogasil's current Enterprise Value is R$39,414 Mil.
Raia Drogasil's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$4,258 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a EV-to-EBITDA of 9.26 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Raia Drogasil. This is 46% below median its historical median of 17.07. Over the past decade, Raia Drogasil's EV-to-EBITDA has ranged from 8.22 to 33.82. According to the industry distribution chart, Raia Drogasil ranks #209 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 40.7%.
Is Raia Drogasil's EV-to-EBITDA too high?
Raia Drogasil's current EV-to-EBITDA of 9.26 is 46% below median its 10-year median of 17.07. Over the past 10 years, this metric has ranged from a low of 8.22 to a high of 33.82. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.81. Raia Drogasil's value of 9.26 is 14.3% below this industry median. Based on the distribution chart, Raia Drogasil ranks #209 out of 513 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #209 out of 513 companies for EV-to-EBITDA. This puts Raia Drogasil in the upper half of its industry. The industry median EV-to-EBITDA is 10.81. Raia Drogasil's value of 9.26 is 14.3% below this benchmark. Historically, Raia Drogasil's own EV-to-EBITDA has ranged from 8.22 to 33.82 over the past decade. While the company's 10-year median is 17.07 vs. the industry median of 10.81, Raia Drogasil has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.81, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current EV-to-EBITDA of 9.26 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Raia Drogasil. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current EV-to-EBITDA is 9.26, which is 46% below median its own 10-year median of 17.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$27.20, compared to a current price of R$18.00 — trading 33.8% below its estimated fair value. The current EV-to-EBITDA is 9.26, which is 46% below median its 10-year median of 17.07 and 14.3% below the Healthcare Providers & Services industry median of 10.81. Raia Drogasil's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current EV-to-EBITDA is 9.26 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.00 is trading 33.8% below its estimated GF Value™ of R$27.20.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
EV-to-EBITDA: 9.26 (46% below median its 10-year median of 17.07)
GF Value™: R$27.20 vs. price of R$18.00 (33.8% below fair value)
Industry Position: 14.3% below the Healthcare Providers & Services median (#209 of 513)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
90GF Score
Get the complete analysis for BSP:RADL3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
